Mays Cancer Center studies help spur leukemia drug’s approval
The FDA has approved pacritinib for myelofibrosis patients with low platelet counts. Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the […]